Managed Healthcare Executive October 16, 2024
Large PBMs are removing Humira from some of their formularies. AMCP Nexus panelists still see challenges and a need for education and more attention to patient interests.
Although there are now 10 biosimilars to Humira (adalimumab) on the market, they are struggling to compete against their brand-name reference product, the top-selling drug of all time, according to panelists at session today on increasing adoption of Humira biosimilars at the 2024 Academy of Managed Care Pharmacy Nexus in Las Vegas.
“Penetration is very low compared to the number of products that we have on the market,” said Justin Bioc, Pharm.D., head of clinical pharmacy at Devoted Health, a health insurance startup.
Bioc said the contrast to the generics to small-molecule drugs...
Today's Sponsors
Today's Sponsor